National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 7) (No. PB 60 of 2012)

Link to law: https://www.comlaw.gov.au/Details/F2012L01683

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
PB 60 of 2012
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012
(No. 7)1
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.
Dated 9 August 2012
 
 
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1          Name of Instrument
            (1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 7).
            (2)        This Instrument may also be cited as PB 60 of 2012.
2          Commencement
Schedule 1 to this Instrument commences on 1 August 2012, immediately following commencement of PB 44 of 2012.
            Schedule 2 to this Instrument commences on 1 September 2012.
3          Amendment of the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010)
            Schedules 1 and 2 amend the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010).
Schedule 1     Amendment
 
[1]           Schedule 4, Part 1, after entry for Ranibizumab
insert:
Rasagiline
C4053
 
Parkinson disease
Compliance with Authority Required procedures – Streamlined Authority Code 4053
 
Schedule 2     Amendments
 
[1]           Schedule 1, entry for Amoxycillin in the form Capsule 250 mg (as trihydrate) [Max Quantity 20; Number of Repeats 0]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Amoxycillin-PS
FZ
PDP
 
 
20
0
 
[2]           Schedule 1, entry for Amoxycillin in the form Capsule 250 mg (as trihydrate) [Max Quantity 20; Number of Repeats 1]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Amoxycillin-PS
FZ
MP NP MW
 
 
20
1
 
[3]           Schedule 1, entry for Amoxycillin in the form Capsule 500 mg (as trihydrate) [Max Quantity 20; Number of Repeats 0]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Amoxycillin-PS
FZ
PDP
 
 
20
0
 
[4]           Schedule 1, entry for Amoxycillin in the form Capsule 500 mg (as trihydrate) [Max Quantity 20; Number of Repeats 1]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Amoxycillin-PS
FZ
MP NP MW
 
 
20
1
 
[5]           Schedule 1, entry for Azathioprine in the form Tablet 50 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Azathioprine-PS
FZ
MP NP
 
 
100
5
 
[6]           Schedule 1, entry for Calcipotriol
omit:
 
Scalp solution 50 micrograms (as monohydrate) per mL, 30 mL
Application
Daivonex
LO
MP NP
C2963
 
1
1
 
[7]           Schedule 1, entry for Cefepime
omit from the column headed “Form” (twice occurring):
(with any determined brand of sodium chloride injection as the required solvent)
[8]           Schedule 1, entry for Ceftriaxone
omit:
 
 
Powder for injection 500 mg (as sodium)
Injection
Ceftriaxone ICP
PP
MP NP
C1143 C1169 C1846 C1847
P1143
1
0
 

 
 
 
 
 
MP NP
C1143 C1169 C1846 C1847
P1169 P1846 P1847
5
0
 

substitute:
 
 
Powder for injection 500 mg (as sodium)
Injection
Ceftriaxone-AFT
AE
MP NP
C1143 C1169 C1846 C1847
P1143
1
0
 

 
 
 
Ceftriaxone ICP
PP
MP NP
C1143 C1169 C1846 C1847
P1143
1
0
 

 
 
 
Ceftriaxone-AFT
AE
MP NP
C1143 C1169 C1846 C1847
P1169 P1846 P1847
5
0
 

 
 
 
Ceftriaxone ICP
PP
MP NP
C1143 C1169 C1846 C1847
P1169 P1846 P1847
5
0
 

[9]           Schedule 1, entry for Citalopram in the form Tablet 20 mg (as hydrobromide)
omit:
 
 
 
A-Citalopram
TA
MP NP
C1211
 
28
5
 
[10]         Schedule 1, entry for Clarithromycin in the form Tablet 250 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Clarithromycin-PS
FZ
MP NP
 
 
14
1
 
[11]         Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as hydrogen sulfate)
omit:
 
 
 
Pharmacor Clopidogrel 75
CR
MP NP
C1719 C1720 C1721 C1722 C1723 C1724
 
28
5
 
[12]         Schedule 1, entry for Cyclosporin in the form Capsule 25 mg [Max Quantity 60; Number of Repeats 3]
(a) omit:
 
 
 
Cicloral
SZ
MP
C2049 C2050 C2051 C2052 C2053
 
60
3
 
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Cyclosporin Sandoz
SZ
MP
C2049 C2050 C2051 C2052 C2053
 
60
3
 
[13]         Schedule 1, entry for Cyclosporin in the form Capsule 25 mg [Max Quantity 120; Number of Repeats 5]
(a) omit:
 
 
 
Cicloral
SZ
MP
See Note 1
C1654 C1655 C1656 C1657 C1658 C3328 C3329 C3330 C3331 C3332
 
120
5
C
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Cyclosporin Sandoz
SZ
MP
See Note 1
C1654 C1655 C1656 C1657 C1658 C3328 C3329 C3330 C3331 C3332
 
120
5
C
[14]         Schedule 1, entry for Cyclosporin in the form Capsule 50 mg [Max Quantity 60; Number of Repeats 3]
(a) omit:
 
 
 
Cicloral
SZ
MP
C2049 C2050 C2051 C2052 C2053
 
60
3
 
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Cyclosporin Sandoz
SZ
MP
C2049 C2050 C2051 C2052 C2053
 
60
3
 
[15]         Schedule 1, entry for Cyclosporin in the form Capsule 50 mg [Max Quantity 120; Number of Repeats 5]
(a) omit:
 
 
 
Cicloral
SZ
MP
See Note 1
C1654 C1655 C1656 C1657 C1658 C3328 C3329 C3330 C3331 C3332
 
120
5
C
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Cyclosporin Sandoz
SZ
MP
See Note 1
C1654 C1655 C1656 C1657 C1658 C3328 C3329 C3330 C3331 C3332
 
120
5
C
 
[16]         Schedule 1, entry for Cyclosporin in the form Capsule 100 mg [Max Quantity 60; Number of Repeats 3]
(a) omit:
 
 
 
Cicloral
SZ
MP
C2049 C2050 C2051 C2052 C2053
 
60
3
 
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Cyclosporin Sandoz
SZ
MP
C2049 C2050 C2051 C2052 C2053
 
60
3
 
[17]         Schedule 1, entry for Cyclosporin in the form Capsule 100 mg [Max Quantity 120; Number of Repeats 5]
(a) omit:
 
 
 
Cicloral
SZ
MP
See Note 1
C1654 C1655 C1656 C1657 C1658 C3328 C3329 C3330 C3331 C3332
 
120
5
C
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Cyclosporin Sandoz
SZ
MP
See Note 1
C1654 C1655 C1656 C1657 C1658 C3328 C3329 C3330 C3331 C3332
 
120
5
C
[18]         Schedule 1, entry for Cyproterone in the form Tablet containing cyproterone acetate 50 mg [Max Quantity 20; Number of Repeats 5]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Cyprocur 50
QA
MP
C1014 C1230 C1404
P1230
20
5
 
[19]         Schedule 1, entry for Cyproterone in the form Tablet containing cyproterone acetate 50 mg [Max Quantity 100; Number of Repeats 5]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Cyprocur 50
QA
MP
C1014 C1230 C1404
P1014 P1404
100
5
 
[20]         Schedule 1, entry for Dicloxacillin in each of the forms: Capsule 250 mg (as sodium); and Capsule 500 mg (as sodium)
omit:
 
 
 
Dicloxsig
QA
MP NP MW PDP
C1345
 
24
0
 
[21]         Schedule 1, omit entry for Dihydroergotamine
[22]         Schedule 1, entry for Diltiazem in the form Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg
omit:
 
 
 
Diltahexal CD
HX
MP NP
 
 
30
5
 
[23]         Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL [Docetaxel Sandoz]
insert in numerical order in the column headed “Circumstances”:
C3892
[24]         Schedule 1, entry for Docetaxel
omit:
 
Injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL with solvent
Injection
Taxotere
SW
MP
C3186 C3888 C3890 C3892 C3916 C3955 C3956 C7002
See Note 3
See Note 3
See Note 3
D
[25]         Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL [Docetaxel Sandoz]
insert in numerical order in the column headed “Circumstances”:
C3892
[26]         Schedule 1, omit entry for Etidronic Acid
[27]         Schedule 1, omit entry for Etidronic Acid and Calcium
[28]         Schedule 1, entry for Famotidine in the form Tablet 20 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Famotidine-PS
FZ
MP NP
 
 
60
5
 
[29]         Schedule 1, entry for Famotidine in the form Tablet 40 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Famotidine-PS
FZ
MP NP
 
 
30
5
 
[30]         Schedule 1, entry for Fluconazole in the form Solution for I.V. infusion 200 mg in 100 mL
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Fluconazole Alphapharm
AF
MP NP
C3613 C3614 C3615 C3616 C3617 C3618
 
7
0
 
[31]         Schedule 1, entry for Fluconazole in the form Solution for I.V. infusion 400 mg in 200 mL
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Fluconazole Alphapharm
AF
MP NP
C3613 C3614 C3615 C3616 C3617 C3618
 
1
0
 
[32]         Schedule 1, entry for Glucose Indicator―Blood
omit:
 
Test strips, 25 (On-Call Plus)
For external use
On-Call Plus
PZ
MP NP
 
 
4
5
 

 
 
 
 
 
MP
 
P3035
4
11
 

[33]         Schedule 1, entry for Isosorbide Mononitrate in the form Tablet 60 mg (sustained release)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Isosorbide-PS
FZ
MP NP
 
 
30
5
 
[34]         Schedule 1, entry for Lamivudine in the form Tablet 100 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Zetlam
AF
MP
See Note 1
C3959 C3960 C3961 C3962
 
56
5
D
[35]         Schedule 1, entry for Lamivudine in the form Tablet 150 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Alphapharm Lamivudine
AF
MP
See Note 1
C3586 C3587 C3588 C3589
 
120
5
D
[36]         Schedule 1, entry for Lamivudine in the form Tablet 300 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Alphapharm Lamivudine
AF
MP
See Note 1
C3586 C3587 C3588 C3589
 
60
5
D
[37]         Schedule 1, entry for Methoxyflurane
omit from the column headed “Responsible Person”: NQ          substitute: DV
[38]         Schedule 1, entry for Methylprednisolone in the form Powder for injection 1 g (as sodium succinate)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Methylprednisolone Alphapharm
AF
MP NP
 
 
1
0
 
[39]         Schedule 1, entry for Omeprazole in the form Tablet 20 mg
(a) omit:
 
 
 
Omeprazole Ranbaxy
RA
MP NP
C1177 C1337 C1476 C1533
P1177
30
1
 
(b) omit:
 
 
 
Omeprazole Ranbaxy
RA
MP NP
C1177 C1337 C1476 C1533
P1337 P1476 P1533
30
5
 
[40]         Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Max Quantity 30;
Number of Repeats 2]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
STADA Pantoprazole
TD
MP NP
C1177 C1337 C1476 C1533
P1177
30
2
 
[41]         Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Max Quantity 30;
Number of Repeats 5]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
STADA Pantoprazole
TD
MP NP
C1177 C1337 C1476 C1533
P1337 P1476 P1533
30
5
 
[42]         Schedule 1, entry for Paracetamol in the form Tablet 500 mg
(a) omit:
 
 
 
Chem mart Paracetamol
XS
PDP
 
 
100
0
 
(b) omit:
 
 
 
Pharmacy Choice Paracetamol
YM
PDP
 
 
100
0
 

 
 
 
Terry White Chemists Paracetamol
YS
PDP
 
 
100
0
 

(c) omit:
 
 
 
Chem mart Paracetamol
XS
MP NP
 
 
100
1
 
 
(d) omit:
 
 
 
Pharmacy Choice Paracetamol
YM
MP NP
 
 
100
1
 

 
 
 
Terry White Chemists Paracetamol
YS
MP NP
 
 
100
1
 

(e) omit:
 
 
 
Chem mart Paracetamol
XS
PDP
 
P2046
300
0
 
(f) omit:
 
 
 
Pharmacy Choice Paracetamol
YM
PDP
 
P2046
300
0
 

 
 
 
Terry White Chemists Paracetamol
YS
PDP
 
P2046
300
0
 

(g) omit:
 
 
 
Chem mart Paracetamol
XS
MP NP
 
P2046
300
4
 
(h) omit:
 
 
 
Pharmacy Choice Paracetamol
YM
MP NP
 
P2046
300
4
 

 
 
 
Terry White Chemists Paracetamol
YS
MP NP
 
P2046
300
4
 

[43]         Schedule 1, entry for Pioglitazone in the form Tablet 15 mg (as hydrochloride)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Prioten 15
DO
MP NP
C3540 C3541 C3542
 
28
5
 
[44]         Schedule 1, entry for Pioglitazone in the form Tablet 30 mg (as hydrochloride)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Prioten 30
DO
MP NP
C3540 C3541 C3542
 
28
5
 
[45]         Schedule 1, entry for Pioglitazone in the form Tablet 45 mg (as hydrochloride)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Prioten 45
DO
MP NP
C3540 C3541 C3542
 
28
5
 
[46]         Schedule 1, entry for Risperidone in the form Tablet 0.5 mg [Max Quantity 60; Number of Repeats 2]
(a) omit:
 
 
 
Risperidone Actavis 0.5
TA
MP NP
C1589 C2061 C3083
P2061 P3083
60
2
 
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Risperidone GH
GQ
MP NP
C1589 C2061 C3083
P2061 P3083
60
2
 
[47]         Schedule 1, entry for Risperidone in the form Tablet 0.5 mg [Max Quantity 60; Number of Repeats 5]
(a) omit:
 
 
 
Risperidone Actavis 0.5
TA
MP NP
C1589 C2061 C3083
P1589
60
5
 
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Risperidone GH
GQ
MP NP
C1589 C2061 C3083
P1589
60
5
 
[48]         Schedule 1, entry for Risperidone in the form Tablet 1 mg [Max Quantity 60; Number of Repeats 2]
omit:
 
 
 
Risperidone Actavis 1
TA
MP NP
C1589 C2061 C2272 C3083
P2061 P3083
60
2
 
[49]         Schedule 1, entry for Risperidone in the form Tablet 1 mg [Max Quantity 60; Number of Repeats 5]
omit:
 
 
 
Risperidone Actavis 1
TA
MP NP
C1589 C2061 C2272 C3083
P1589 P2272
60
5
 
[50]         Schedule 1, entry for Risperidone in the form Tablet 2 mg [Max Quantity 60; Number of Repeats 2]
omit:
 
 
 
Risperidone Actavis 2
TA
MP NP
C1589 C2272 C3083
P3083
60
2
 
[51]         Schedule 1, entry for Risperidone in the form Tablet 2 mg [Max Quantity 60; Number of Repeats 5]
omit:
 
 
 
Risperidone Actavis 2
TA
MP NP
C1589 C2272 C3083
P1589 P2272
60
5
 
[52]         Schedule 1, entry for Risperidone in the form Tablet 3 mg
omit:
 
 
 
Risperidone Actavis 3
TA
MP NP
C1589 C2272
 
60
5
 
[53]         Schedule 1, entry for Risperidone in the form Tablet 4 mg
omit:
 
 
 
Risperidone Actavis 4
TA
MP NP
C1589 C2272
 
60
5
 
[54]         Schedule 1, entry for Simvastatin in each of the forms: Tablet 5 mg; Tablet 10 mg; and Tablet 20 mg
(a) omit:
 
 
 
Simvahexal
HX
MP
C1540 C3047
P1540
30
5
 

 
 
 
 
 
NP
C1540
 
30
5
 

(b) omit:
 
 
 
Simvahexal
HX
MP
C1540 C3047
P3047
30
11
 
[55]         Schedule 1, entry for Sodium Chloride
omit:
 
Injection 9 mg per mL, 10 mL
Injection/
solvent for injectables
Pfizer Australia Pty Ltd
PF
PDP
 
 
5
0
 

 
 
 
 
 
MP NP
 
 
5
1
 

[56]         Schedule 1, entry for Somatropin
(a) omit:
 
 
Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)
Injection
Norditropin FlexPro
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Norditropin NordiFlex
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Norditropin SimpleXx
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Omnitrope
SZ
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

substitute:
 
Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)
Injection
Norditropin SimpleXx
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Omnitrope
SZ
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative) in pre-filled pen
Injection
Norditropin FlexPro
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Norditropin NordiFlex
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

(b) omit:
 
 
Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)
Injection
Norditropin FlexPro
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Norditropin NordiFlex
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Norditropin SimpleXx
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Omnitrope
SZ
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

substitute:
 
Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)
Injection
Norditropin SimpleXx
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Omnitrope
SZ
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative) in pre-filled pen
Injection
Norditropin FlexPro
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Norditropin NordiFlex
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

(c) omit:
 
 
Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)
Injection
Norditropin FlexPro
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Norditropin NordiFlex
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Norditropin SimpleXx
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

substitute:
 
Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)
Injection
Norditropin SimpleXx
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative) in pre-filled pen
Injection
Norditropin FlexPro
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

 
 
 
Norditropin NordiFlex
NO
MP
See Note 1
See Note 3
See Note 3
See Note 3
See Note 3
D

[57]         Schedule 1, entry for Sumatriptan in the form Tablet 50 mg (as succinate)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Sumatriptan-PS
FZ
MP NP
C3233
 
4
5
 
[58]         Schedule 1, entry for Ticarcillin with Clavulanic Acid
omit from the column headed “Form”:
(with any determined brand of sodium chloride injection as the required solvent)
[59]         Schedule 1, entry for Timolol in the form Eye drops 2.5 mg (as maleate) per mL, 5 mL
omit:
 
 
 
Timoptol
FR
MP AO
 
 
1
5
 
[60]         Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Max Quantity 30; Number of Repeats 5]
(a) omit:
 
 
 
Valaclovir Actavis 500
TA
MP NP
C3622 C3623 C3624 C3631
P3623 P3624
30
5
 
(b) omit from the column headed “Responsible Person” for the brand “Valacor 500”:     QR          substitute: CR
[61]         Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Max Quantity 42; Number of Repeats 0]
(a) omit:
 
 
 
Valaciclovir Actavis 500
TA
MP NP
C3622 C3623 C3624 C3631
P3622 P3631
42
0
 
(b) omit from the column headed “Responsible Person” for the brand “Valacor 500”:     QR          substitute: CR
[62]         Schedule 1, entry for Verapamil
omit:
 
Tablet containing verapamil hydrochloride 160 mg
Oral
Isoptin
AB
MP NP
 
 
60
5
 
 
[63]         Schedule 3, after details relevant to Responsible person code DO
insert:
DV
Medical Developments International Limited
 14 106 340 667
[64]         Schedule 3
omit:
PZ
Prohealth Asia Pacific Pty Ltd
 25 076 852 769
[65]         Schedule 3
omit:
QR
Ranbaxy Australia Pty Limited
 17 110 871 826
[66]         Schedule 3
omit:
XS
Symbion Pty Ltd
 25 000 875 034
[67]         Schedule 3
omit:
YM
Symbion Pty Ltd
 25 000 875 034
[68]         Schedule 3
omit:
YS
Symbion Pty Ltd
 25 000 875 034
[69]         Schedule 4, Part 1, entry for Calcipotriol
omit:
 
C2963
 
Chronic stable plaque type psoriasis vulgaris of the scalp
 
[70]         Schedule 4, Part 1, omit entry for Etidronic Acid
[71]         Schedule 4, Part 1, omit entry for Etidronic Acid and Calcium
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.frli.gov.au.